Safety and Efficacy Study for AKB-6548 in Participants With Chronic Kidney Disease and Anemia

Exclusion Criteria

• •BMI \> 40
• •Red blood cell transfusion within 12 weeks.
• •Androgen therapy within the previous 21 days prior to study dosing
• •Therapy with any approved or experimental erythropoiesis stimulating agent (ESA) within the 10 weeks prior to the Screening visit
• •Participants meeting the criteria of ESA resistance within the previous 4 months
• •Individual doses of intravenous iron of 250 mg or larger within the past 21 days
• •AST or ALT \>1.8x ULN.
• •Alkaline phosphatase \>2x ULN.
• •Total bilirubin \>1.5x ULN.
• •Uncontrolled hypertension
• •New York Heart Association Class III or IV congestive heart failure
• •Myocardial infarction, acute coronary syndrome, or stroke within 6 months prior to dosing